Limits...
Effective dosage and administration schedule of oral alendronate for non-nociceptive symptoms in rats with chronic constriction injury.

Im S, Lim SH, Lee JI, Ko YJ, Park JH, Hong BY, Park GY - J. Korean Med. Sci. (2010)

Bottom Line: On the 14th day post-CCI, the HE group showed significant reduction in thickness and temperature (P<0.001).On the 42nd day post-CCI, the HE group showed significant reduction in temperature compared to the NT group (P<0.001).Also, both HE and HL groups showed statistically significant increased tibia BMD (P<0.001), along with increase of tibia bone strength compared to the NT group.

View Article: PubMed Central - PubMed

Affiliation: Department of Rehabilitation Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea.

ABSTRACT
We evaluated the efficacy of oral alendronate with different dosing regimens for non-nociceptive symptoms and osteoporosis in a sciatic nerve chronic constriction injury (CCI) model. Male Sprague-Dawley rats (n=60) were subdivided into sham control (SC) group and CCI groups, which were divided according to dosage and time of oral alendronate administration: no treatment (NT), low dosage early (LE), high dosage early (HE), low dosage late (LL) and high dosage late (HL). We measured the thickness and temperature of the hind paw, bone mineral density (BMD) of the tibia, along with tibia bone strength. On the 14th day post-CCI, the HE group showed significant reduction in thickness and temperature (P<0.001). On the 42nd day post-CCI, the HE group showed significant reduction in temperature compared to the NT group (P<0.001). Also, both HE and HL groups showed statistically significant increased tibia BMD (P<0.001), along with increase of tibia bone strength compared to the NT group. Based on these findings, early alendronate in high dosages is effective in the non-nociceptive symptoms; early and late alendronate in high dosages, are effective in preventing bone dystrophic changes in a CCI model.

Show MeSH

Related in: MedlinePlus

Efficacy of oral alendronate in different dosage and time of administration in BMD of the affected tibia from Sprague-Dawley rats.*P<0.001 as compared with the NT group; †P<0.001 as compared with the SC group.BMD, bone mineral density; CCI, chronic constriction injury; SC, sham control; NT, no treatment; LE, low dosage early treatment; HE, high dosage early treatment; LL, low dosage late treatment; HL, high dosage late treatment.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2877239&req=5

Figure 3: Efficacy of oral alendronate in different dosage and time of administration in BMD of the affected tibia from Sprague-Dawley rats.*P<0.001 as compared with the NT group; †P<0.001 as compared with the SC group.BMD, bone mineral density; CCI, chronic constriction injury; SC, sham control; NT, no treatment; LE, low dosage early treatment; HE, high dosage early treatment; LL, low dosage late treatment; HL, high dosage late treatment.

Mentions: Prior to, and 14 days after CCI, tibia BMD showed no significant differences between groups (Fig. 3). Forty two days after CCI, tibia BMDs of the 2 high dosage and SC group were higher than that of the NT group (P<0.001). BMDs of tibia for the NT and LL group were significantly reduced than that of the SC group (P<0.001) (Table 1).


Effective dosage and administration schedule of oral alendronate for non-nociceptive symptoms in rats with chronic constriction injury.

Im S, Lim SH, Lee JI, Ko YJ, Park JH, Hong BY, Park GY - J. Korean Med. Sci. (2010)

Efficacy of oral alendronate in different dosage and time of administration in BMD of the affected tibia from Sprague-Dawley rats.*P<0.001 as compared with the NT group; †P<0.001 as compared with the SC group.BMD, bone mineral density; CCI, chronic constriction injury; SC, sham control; NT, no treatment; LE, low dosage early treatment; HE, high dosage early treatment; LL, low dosage late treatment; HL, high dosage late treatment.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2877239&req=5

Figure 3: Efficacy of oral alendronate in different dosage and time of administration in BMD of the affected tibia from Sprague-Dawley rats.*P<0.001 as compared with the NT group; †P<0.001 as compared with the SC group.BMD, bone mineral density; CCI, chronic constriction injury; SC, sham control; NT, no treatment; LE, low dosage early treatment; HE, high dosage early treatment; LL, low dosage late treatment; HL, high dosage late treatment.
Mentions: Prior to, and 14 days after CCI, tibia BMD showed no significant differences between groups (Fig. 3). Forty two days after CCI, tibia BMDs of the 2 high dosage and SC group were higher than that of the NT group (P<0.001). BMDs of tibia for the NT and LL group were significantly reduced than that of the SC group (P<0.001) (Table 1).

Bottom Line: On the 14th day post-CCI, the HE group showed significant reduction in thickness and temperature (P<0.001).On the 42nd day post-CCI, the HE group showed significant reduction in temperature compared to the NT group (P<0.001).Also, both HE and HL groups showed statistically significant increased tibia BMD (P<0.001), along with increase of tibia bone strength compared to the NT group.

View Article: PubMed Central - PubMed

Affiliation: Department of Rehabilitation Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea.

ABSTRACT
We evaluated the efficacy of oral alendronate with different dosing regimens for non-nociceptive symptoms and osteoporosis in a sciatic nerve chronic constriction injury (CCI) model. Male Sprague-Dawley rats (n=60) were subdivided into sham control (SC) group and CCI groups, which were divided according to dosage and time of oral alendronate administration: no treatment (NT), low dosage early (LE), high dosage early (HE), low dosage late (LL) and high dosage late (HL). We measured the thickness and temperature of the hind paw, bone mineral density (BMD) of the tibia, along with tibia bone strength. On the 14th day post-CCI, the HE group showed significant reduction in thickness and temperature (P<0.001). On the 42nd day post-CCI, the HE group showed significant reduction in temperature compared to the NT group (P<0.001). Also, both HE and HL groups showed statistically significant increased tibia BMD (P<0.001), along with increase of tibia bone strength compared to the NT group. Based on these findings, early alendronate in high dosages is effective in the non-nociceptive symptoms; early and late alendronate in high dosages, are effective in preventing bone dystrophic changes in a CCI model.

Show MeSH
Related in: MedlinePlus